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AbstrAct
Natural killer T (NKT) cells constitute a unique subset of innate-like T lymphocytes 
which differ from conventional T cells by recognizing lipid antigens presented by 
the non-polymorphic major histocompatibility complex (MHC) I-like molecule CD1d. 
Despite being a relatively infrequent population of lymphocytes, NKT cells can 
respond rapidly upon activation with glycosphingolipids by production of cytokines 
which aim to polarize different axes of the immune system. Due to their dual effector 
capacities, NKT cells can play a vital role in cancer immunity, infection, inflammation 
and autoimmune diseases. It is believed that modulation of their activity towards 
immune activation can be a useful tool in anti-tumor immunotherapeutic strategies. 
Here we summarize the characteristics of NKT cells and discuss their involvement 
in immunosurveillance. Furthermore, an update is given about their role and the 
progress that has been made in the field of multiple myeloma (MM). Finally, some 
challenges are discussed that are currently hampering further progress.
NAturAl killer t cells: subsets 
ANd fuNctioN
Natural killer T (NKT) cells constitute a highly 
conserved heterogeneous subset of innate-like T 
lymphocytes. This small population owns unique 
phenotypic and functional properties that set them apart 
from conventional T cells by exhibiting characteristics of 
both the innate and the adaptive immune system [1, 2]. 
They diverge from conventional T cells by recognizing 
foreign and self (glyco)sphingolipid antigens presented by 
the non-polymorphic major histocompatibility complex 
(MHC) I-like molecule CD1d, expressed on professional 
antigen-presenting cells (APCs) [2, 3]. Originally NKT 
cells were defined as expressing both the CD3 and αβ T-cell 
receptors (TCR) and lineage markers from natural killer 
(NK) cells, such as CD56 or CD161 (human) and NK1.1 
(murine). It is now generally accepted that this description 
is no longer accurate since these cells only seem to be a 
part of the broader NKT-cell family [4]. Moreover, NKT 
cells have a remarkable capacity to produce extensive 
amounts of cytokines upon stimulation to activate NK 
cells, dendritic cells (DC), regulatory and conventional T 
cells and B cells [5, 6]. Thereby enhancing a cascade of 
complementary cytokines and chemokines and stimulating 
additional populations to mediate immune surveillance 
[6]. Due to their broad cytokine profile, NKT cells can 
both exert an immune enhancing and immunosuppressive 
role and play therefore a vital role in various pathologies, 
such as cancer, infection, inflammation and autoimmune 
diseases [6-11]. Modulating their activity towards immune 
activation could be a useful tool for improving vaccines in 
cancer, infectious diseases and other therapeutic settings.
type i natural killer t cells
 The type I NKT cells also referred to as “invariant” 
NKT cells (iNKT) are the main studied subpopulation of 
NKT cells and are usually linked to promotion of tumor 
immunity. They express a semi-invariant TCRα chain 
(Vα14-Jα18 in mice, Vα24-Jα18 in humans) paired with a 
heterogeneous Vβ chain repertoire (Vβ2, 7 or 8.2 in mice 
and Vβ11 in humans) [2]. Type I NKT cells often express 
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other NK surface markers such as NK1.1 (in some mouse 
strains) or CD161 (in human), NKG2D, CD44, CD56, 
CD69, CD94, CD122 and members of the Ly49 family 
[8, 9]. iNKT cells can be further subdivided according to 
their CD4/CD8 co-receptor expression: CD4+ and CD4-
CD8-  (DN) subsets, and a small subset of CD8+ cells 
(only human) have been described [12-14]. Type I NKT 
cells are present in different tissues, such as the spleen 
(0,2-0,5% of the T lymphocytes), bone marrow, thymus, 
lymph nodes and blood (0,01-0,5% of the T lymphocytes) 
in mice [12, 15]. The highest frequency is found in the 
liver with around 10 to 30% of all T lymphocytes [16]. 
These hepatic iNKT cells possess a strong anti-tumor 
capacity and show different functional characteristics 
than the NKT cells from other tissues [15]. In humans, 
type I NKT cells appear to be approximately 10 times less 
abundant in the liver than in mice while for the spleen, 
bone marrow, blood and lymph nodes the ranges remain 
similar. The highest prevalence is found in the omentum, 
representing 10% of the white adipose tissue T cell 
population, whereas their frequency and number in the 
peripheral circulation vary widely between individuals 
[1, 8, 12, 17]. Identifying lipid antigens recognized by 
NKT cells is still an ongoing challenge. Type I NKT 
respond to α- and β-linked glycosphingolipids among 
which α-Galactosylceramide (αGalCer, KRN700), an 
exogenous synthetic glycolipid originally extracted from 
the marine sponge Agelas mauritianus or microorganisms 
symbiotic with the sponge [4, 18]. αGalCer is the 
most-well characterized agonist for type I NKT cells 
in humans and mice and shows a very potent capacity 
to induce cytokine release by iNKT cells [2] . Today, 
several new analogues of αGalCer, showing weaker 
or stronger agonistic potential, have been synthetized 
including, α-C-GalCer, naphthylurea 6”-derived α-GalCer 
(NU- α-GalCer), C20:2, DB06-1 and OCH [19]. Also 
microbial and self-glycolipid iNKT cell antigens 
such as ceramide structures (Sphingomonas species), 
diacylglycerols (Borrelia burgdorferi and Streptococcus 
pneumoniae), cholesteryl-sugars (Helicobacter pylori) 
but also phospholipids (Mycobacterium tuberculosis), the 
lysosomal glycosphingolipid isoglobotrihexosylceramide 
(iGb3) and the peroxisomal derived lipid plasmalogen 
lysophosphatidylcholine (lyso-PC) have been identified 
[20-26]. More recently, in their quest to find new 
endogenous ligands Kain et al. revealed the presence of 
mammalian α-linked glucosylceramides [27]. This defies 
the previous hypothesis where it was thought that humans 
were not able to make α-linked sugar moieties due to the 
presence of natural anti-α-linked sugar antibodies [28]. 
Direct CD1d-agonist stimulation of the TCR complex is 
accompanied by the rapid and robust release of T-helper 
1 (Th1), Th2 and Th17 cytokines, including interferon-
gamma (IFN-γ), interleukins (IL)-2, -4, -10, -13, -17, -21 
and 22, granulocyte-macrophage colony-stimulating factor 
(GM-CSF) and tumor necrosis factor-alpha (TNFα) [3, 8, 
11] (Figure 1). In addition, it was reported that cytolysis 
in a perforin-dependent manner, through the Fas-FasL 
axis or through expression of intracellular granzyme B 
is also promoted upon iNKT stimulation [29-31]. Similar 
to conventional T cells, through the engagement of 
costimulatory pathways such as CD40-CD40L and B7-
CD28, DC are induced to maturate and secrete IL-12. 
In turn, IL-12 stimulates NK, NKT, and other T cells to 
produce IFN-γ which subsequently activates bystander 
cell activity and stimulates more downstream effector 
populations such as NK cells, CD8+ T cells and γδ cells 
[8]. Type I NKT cells are indirectly activated in response 
to pattern-recognition receptor (PRR) of toll-like receptor 
(TLR) signalling by APCs together with presentation of 
self-antigens through CD1d, inducing cytokine secretion 
by APCs such as IL-12, IL-18 and type I α/β IFNs [8, 
22, 32, 33] (Figure 1). Also during inflammation, type 
I NKT cells can be stimulated in a TCR independent 
manner by different stimulatory and co-stimulatory 
signals, such as engagement of peroxisome proliferator 
activated receptor (PPAR)γ through bacterial products 
such as lipopolysaccharide (LPS) [32,34]. Activation of 
Fcγ receptors by antigen-IgG complexes, interaction of 
NK1.1 receptors with their ligands on APCs and activation 
of TLRs of previously activated type I NKT cells also take 
part in additional activation mechanisms of type I NKT 
cells [32].
type ii natural killer t cells
Type II NKT cells are a CD1d-restricted subset that 
expresses more diverse αβ-TCRs (for example Vα3.2Jα9 
or Vα8 with Vβ8 TCRβ-chain). They have an activated 
or memory phenotype and many also express NK 
surface markers [3, 35]. Moreover, they have the ability 
to suppress autoimmunity and inhibit tumor rejection. 
In contrast to type I NKT cells, their distribution and 
physiological role is less understood. They compromise 
a minor subset in mice but constitute a major subgroup of 
the T cells in the bone marrow, liver and gut of humans 
[16, 36]. Type II NKT cells are non-reactive to α-GalCer. 
Currently, the most widely studied type II NKT antigen 
is sulfatide, a glycolipid abundantly present in neuronal 
tissue, liver, kidney and pancreas [37, 38]. Recent research 
also identified a range of hydrophobic antigens, such 
as lysosulfatide, lyso-PC, small aromatic (non-lipid) 
molecules and other lipids such as β-Glucosylceramide 
(β-GlcCer)(C24:0) and β-Galactosylceramide (β-GalCer) 
as being potential activators of type II NKT cells [39-42]. 
other invariant like t cells
Next to the different subsets of NKT cells, it is 
worth to briefly mention another population of semi-
invariant T cells, called mucosal associated invariant T 
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cells or MAIT cells. They are restricted to a monomorphic 
MHC I-like molecule MR1. Similar to NKT cells, they 
express an invariant TCRα-chain (Vα33Jα19 in mice and 
Vα7.2α19 in humans) combined with a limited but not 
invariant range of TCRβ-chains [43]. Rare in laboratory 
mice, they appear to be a very significant subset of T 
cells in humans, accounting for 1-10% of T cells in 
peripheral blood and being predominantly present in liver 
and mucosal tissues. Surprisingly, a completely new and 
unexpected class of antigens was shown to be presented 
by MRI molecules to MAIT cells, namely vitamin B2 
(riboflavin) metabolites [44-46]. Although these cells are 
not CD1d restricted, their similarities with NKT cells are 
intriguing [47]. Research on MAIT cells has till now been 
hampered due to the lack of identification tools and the 
unknown nature of the antigens. However, very recently 
Reantragoon et al. were able to develop MR1 tetramers 
which allowed them to better phenotypically characterize 
human and mouse MAIT cells [48]. This development will 
lead to an increased understanding of the nature of MAIT 
cells. Also γδ T cells belong to this non-conventional 
invariant T cell group. Being innate-like lymphocytes, 
they differ from conventional αβ T cells since they do not 
express the CD4 and CD8 co-receptors but express Toll-
like receptors and share a number of markers with NK 
cells [49]. Subsequently, antigen recognition by γδ TCR 
is not restricted to MHC molecules. γδ TCR recognize a 
diverse array of self and nonself-antigens, such as small 
peptides, soluble or membrane proteins, phospholipids, 
prenyl pyrophosphates, and sulfatides, while αβTCR bind 
peptides presented by MHC class I or class II molecules. 
In humans, γδ T cells represent 0.5-16% (on average: 4%) 
figure 1: Major (i Nkt) cell activation pathways. A. Direct activation of iNKT cells occurs when the TCRVα14/24 interacts with 
a ligand presented by a CD1d molecule present on DCs or other APCs. DCs present exogenous glycosphingolipids such as the synthetic 
α-GalCer or microbial lipid-derived antigens and subsequently activate the iNKT cell. This CD1d dependent activation is followed by 
the secretion of cytokines such as IFN-γ and IL-4. b. Indirect activation of iNKT cells can be induced by cytokine secretion of DCs such 
as IL-12. Engagement of a microbial Ag to the pattern-recognition receptor (PRR) of the toll-like receptor (TLR) present on APCs (e.g 
DCs) triggers IL-12 co-stimulation. IL-12 secreted by DCs binds to its receptor, IL-12R, on iNKT cells which activates iNKT cells by 
inducing IFN-γ secretion. The activation occurs in the presence or absence of self or low affinity endogenous lipid antigens. Besides IL-12, 
also other cytokines such as IL-18 and type I-IFN (α & β) can be secreted and activate iNKT cells in a CD1d independent manner. iNKT, 
Invariant natural killer T; DCs, Dendritic cells; TCR, T cell receptor; α-GalCer, Alpha-Galactosylceramide; IL-12, Interleukin 12, IL-12R; 
Interleukin 12 receptor; TLR, Toll-like receptor; PRR, Pattern-recognition receptor; IFN, Interferon. 
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of all CD3+ cells in adult peripheral blood, and organized 
lymphoid tissues (thymus, tonsil, lymph nodes, and 
spleen), <5% in tongue and reproductive tract and 10-30% 
in intestine. In adult mice, 1-4% of all T cells in thymus, 
secondary lymphoid organs and lung are γδ T cells. γδ T 
cells are more abundant in other mucosal sites where they 
constitute 10-20% of all T cells in female reproductive 
organs, 20-40% of the intestinal intra-epithelial T cells and 
50-70% of skin dermal T cells [50]. Moreover, the γδ TCR 
repertoire is restricted and depends on the tissue type and 
their localization. The conditions that lead to responses of 
γδ T cells are not fully understood, and current concepts 
of them are ‘first line of defense’, ‘regulatory cells’, or 
‘bridge between innate and adaptive responses’.
NAturAl killer t cells: 
iMplicAtioNs iN tuMor iMMuNity
enhancement of tumor immunity
Type I NKT cells are able to kill cancer cells 
directly or indirectly via the downstream activation of 
other innate and adaptive immune cells. Direct NKT 
lysis can be induced by perforin , via the Fas-FasL axis 
or through expression of intracellular granzyme B [29, 
51]. In vitro observations demonstrated that tumor cells 
expressing CD1d were more prone to lysis induced by 
NKT cells [52, 53]. This strengthens the hypothesis that 
high CD1d expression levels on tumor cells correlate with 
lower metastasis rates [53]. However, most of the tumor 
immunosurveillance by type I NKT cells is initiated by 
figure 2: Nkt dysregulation in multiple myeloma. Type I NKT cells are quantitatively and qualitatively defective in MM which 
hampers their anti-tumor potential. A dramatic drop of type I NKT cell number can be observed in tumor mouse models and MM patients. 
CD1d expression levels are down-regulated in advanced MM patients and expression is lost in most of the studied myeloma cell lines. 
Moreover, advanced stages of MM are associated with a progressive loss of function and their capacity to secrete IFN-γ. LEN has the ability 
to induce type I NKT expansion in presence of α-GalCer and to stimulate IFN-γ secretion by NKT cells in MM patients. Combination 
therapy provides downstream activation of NK cells, monocytes and eosinophils and ultimately promotes tumor suppression. A reduction 
of paraprotein is detected in the serum or urine. NKT, Natural killer T; DC, dendritic cells; NK, natural killer; Th, T helper; α-GalCer, 
Alpha-Galactosylceramide; IFN, Interferon.
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Th1 cytokines and is mainly dependent on the recruitment 
and activation of other cytolytic cell populations. In 
fact, large amounts of IFN-γ and cross-activation of NK 
cells are necessary for tumor protection upon α-GalCer 
stimulation. Cytokines such as IL-12 and IL-18 are also 
necessary to reach optimal IFN-γ levels, consequently 
leading to tumor immunity [54-56]. Proof that tumor 
immunosurveillance by type I NKT cells occurs through 
CD1d became clear when adoptive transfer of liver DN 
type I NKT cells from WT into CD1d KO mice (lacking 
all NKT cells) did not confer protection. In Jα18 KO 
mice (missing type I but retain type II NKT cells) the 
NKT cell population was able to be recovered and tumor 
immunity could be rescued upon NKT cell transfer [31, 
57]. Nevertheless, in contrast with CD4+ liver type I 
NKT cells, protection could only be generated using the 
DN liver type I NKT subset. From these studies it can be 
concluded that different subsets of NKT cells can have 
different functions in tumor immunosurveillance [15]. 
Surface marker expression, anatomical origin as well as 
different antigens can alter the immunological capacity and 
function of NKT cells. Type I NKT cells not only increase 
protective cell responses but can also enhance tumor 
immunity by modifying the effects of immunosuppressive 
cells, such as myeloid-derived suppressor cells (MDSCs), 
suppressive IL-10 producing neutrophils and T regulatory 
cells [58-61]. 
suppression of tumor immunity
Type II NKT cells possess an immunosuppressive 
activity in tumor immunology. By counteracting 
type I NKT cells and negatively influencing other 
immune cells they are capable to down-regulate tumor 
immunosurveillance [62, 63]. CD4+ type II NKT cells 
are producing more IL-13 and IL-4 than type I cells [64]. 
By the release of Th2 cytokines, type II NKT cells have 
been shown to suppress autoimmune T cell responses. The 
original observation was made in a 15-12RM fibrosarcoma 
model where CD8+ cytotoxic T cells were suppressed by 
CD4+ type II NKT cells through production of IL-13 
which in turn induced TGF-β, leading to suppression 
of the antitumor activity [64, 65]. Later on, a similar 
observation was also reported in several other solid tumor 
models such as in a CT26 colon carcinoma lung metastasis 
model, a subcutaneous CT26-L5 colon carcinoma model, 
an orthothopic K7M2 osteosarcoma model and a renal cell 
adenocarcinoma liver metastasis model [66]. CD1d KO 
mice and Jα18 KO mice were compared side-by-side in 
different tumor models. CD1d KO mice were resistant to 
tumor growth while Jα18 KO mice behaved similar to wild 
type mice. This confirms the hypothesis that type II NKT 
cells present in Jα18 KO were sufficient for suppression 
of tumor immunosurveillance. Anti-CD4 treatment was 
able to abrogate the retained suppression, consistent with 
the original observation that the suppressing cell type 
has a CD4+ phenotype [66]. Furthermore, direct selective 
stimulation by sulfatide significantly induced growth of 
CT26 lung metastasis. The effect was retained in Jα18 KO 
mice but was lacking in CD1d KO mice. This indicated 
that the effect of sulfatide was only type II NKT cell 
specific. As a result, it was assumed that type II NKT cells 
also suppress anti-tumor immune responses in humans in 
a similar way [62].
Although the immunosuppressive role is often 
attributed to type II NKT cells, there are a number of 
exceptions reported in literature where type I NKT cells 
appear to support immunosuppression [67-69]. Th2 
cytokines (IL-13, TGF-β) produced by type I NKT cells 
conferred immunosuppression, subsequently leading to 
the inhibition of cytotoxic T cells and NK cell activity. 
The outcome of type I NKT cell-activation is dependent 
on different factors such as the antigens, co-stimulatory 
signals and the cytokine milieu which determine the 
plasticity of these cells. Immunosuppressive Tregs have 
been shown to be supported by activated type I NKT cells 
through IL-2 production, but subsequently suppressed 
the NKT cells in a cell-cell contact manner [70]. Two 
studies have reported type I NKT cells capable of 
directly suppressing tumor immunity in animal models of 
hematological malignancies. In a RMA/ T cell lymphoma 
model, NKT deficient mice had augmented cytotoxic T 
cell activity and greater survival rates than WT mice [68]. 
In a model of Burkitt’s-like B cell lymphoma, Jα18 KO 
mice had significantly fewer splenic tumors than WT or 
CD1d KO mice. Stimulation of type I NKT cells with 
α-GalCer did not increase tumor burden, it decreased 
tumor specific CD8+ T cells [67]. 
cross regulation
It has been demonstrated that type I and type II 
NKT subsets not only exert positive or negative effects 
on different cell populations but also cross-regulate each 
other. CD1d KO mice, deficient in both NKT types, 
showed strong resistance towards tumor growth in the 
CT26 colon carcinoma model, whereas Jα18 KO mice, 
lacking only type I NKT cells, showed higher sensitivity to 
tumor growth than WT mice. Consequently, this suggests 
that type I NKT cells may reduce the suppressive effect 
of type II NKT cells [62]. The in vivo activation of type 
II NKT cells by sulfatide enhanced new tumor formation, 
and abrogated or reduced the positive clinical effects 
of α-GalCer when administered together. For example, 
decreased pro-inflammatory cytokine secretion was 
observed, thereby indicating that type II NKT cells may 
also have the ability to suppress type I NKT cell activation. 
Addition of the type II antigen sulfatide in vitro inhibited 
α-GalCer-induced IFN-γ, IL-2, and IL-4 production [50, 
58, 59]. Moreover, Halder RC et al demonstrated by use 
of the model of concanavalin A-induced hepatitis, that 
the activation of sulfatide-reactive type II NKT cells and 
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plasmacytoid DCs in the liver contributed to the anergy, or 
hyporesponsiveness of type I NKT cells [73]. However, it 
is unclear if this mechanism is similar in a tumor setting. 
Nevertheless, the finding that immune-protective type I 
and immune-suppressive type II NKT cells cross-regulate 
each other establishes an NKT regulatory axis and creates 
the opportunity to exploit this knowledge in a clinical 
setting. The success of immunotherapies may depend on 
which way the balance of the axis is shifted. Enhancing 
the activity of type I NKT cells while simultaneously 
blocking type II NKT cells could be a promising strategy 
for future anti-tumor therapies [74].
NAturAl killer t cells: 
iMplicAtioNs iN Multiple 
MyeloMA
Multiple Myeloma (MM) is an incurable 
monoclonal plasma cell malignancy, located primarily 
in the bone marrow (BM), with an incidence of 5 per 
100 000 inhabitants, and affecting approximately 25 000 
new patients yearly in the EU [75]. This haematological 
Tabel 1: Brief overview of α-GalCer–based clinical trials in different cancers
therapeutic setting cancer type clinical outcome
immunological 
responses references
α-GalCer (i.v.) Solid tumors 7 out of 24 patients had stable disease
Increase in IL-12, GM-
CSF and TNF-α, serum 
levels
[103]
α-GalCer-pulsed 
immature Modcs (i.v. & 
i.d.)
metastatic 
malignancies
2 patients out of 12 with decreased 
tumor markers in serum, 1 with 
tumor necrosis
Expansion NKT cells, 
activation of T and NK 
cells, increased IFN-γ 
levels
[30]
α-GalCer-pulsed 
immature Modcs (i.v)
Non-small cell 
lung cancer 
5 out of 9 had no change in 
disease status, 4 patients had 
disease progression, but 1 case had 
increase in NKT cells, 2 cases had 
significant responses
Expansion NKT cells, 
increase in IFN-γ 
mRNA levels
[104]
α-GalCer-pulsed mature 
Modcs (i.v)
Anal cancer 
Renal cell cancer 
Multiple 
myeloma
The patient had stable disease 
The patient had stable disease 
The 3 patients had decreased levels 
of paraprotein in serum or urine
Expansion NKT cells 
and antigen-specific 
memory T cells
[83]
Ex vivo expanded Nkt 
cells with autologous 
α-GalCer-pulsed PBMCs 
(i.v.)
Non-small cell 
lung cancer 
4 out of 6 patients had a stable 
disease, 2 patients had disease 
progression
Expansion NKT cells, 
elevated IFN-γ cell 
number
[105]
α-GalCer-pulsed 
autologous Apcs (via 
nasal submucosa)
Head and neck 
squamous cell 
carcinoma
1 out of 9 patient had a partial 
response, 5 patients had a stable 
disease, 3 patients had disease 
progression
Expansion NKT cells, 
elevated IFN-γ cell 
number in tumor tissue 
and PBMCs
[106]
α-GalCer-pulsed APCs 
(i.v.)
Non-small cell 
lung cancer
5 out of 17 patients had a stable 
disease, the remaining 12 had 
disease progression
Expansion NKT cells, 
elevated IFN-γ cell 
number in tumor tissue 
and PBMCs
[107]
In vitro expanded Nkt 
cells (i.a.) and  α-GalCer-
pulsed Apcs (via nasal 
submucosa)
Head and neck 
squamous cell 
carcinoma
1 out of 8 patients had disease 
progression, 3 patients reacted 
partially, 4 patients had a stable 
disease
Expansion NKT cells, 
elevated IFN-γ cell 
number in tumor tissue 
and PBMCs
[108]
In vitro expanded Nkt 
cells (i.a.) and  α-GalCer-
pulsed Apcs (via nasal 
submucosa)
Head and neck 
squamous cell 
carcinoma 
5 out of 10 patients reacted 
partially, 5 patients had a stable 
disease
Expansion NKT cells, 
elevated IFN-γ cell 
number in tumor tissue 
and PBMCs
[109]
α-GalCer-pulsed mature 
Modcs (i.v) and leN 
(oral, 10mg/day, 3 28 day 
cycles)
Multiple 
myeloma
3 out of 6 patients with decreased 
levels of paraprotein in serum or 
urine
NKT, NK, monocyte 
and  eosinophil 
activation
[90]
α-GalCer: alpha- galactosylceramide; APCs: antigen-presenting cells; GM-CSF: granulocyte macrophage colony-
stimulating factor; i.a.: intraarterial; i.d.:intradermal; i.v.: intravenous; MoDCs: monocyte-derived dendritic cells; NKT: 
natural killer T cells; PBMCs: peripheral blood mononuclear cells; TNF-α: tumor necrosis factor- alpha; LEN: lenalidomide
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malignancy is characterized by the secretion of 
M-proteins in the serum and the urine. Within the BM 
microenvironment different cell types are undergoing 
an evolving crosstalk, promoting tumor cell survival 
and progression. The interwoven stroma provides the 
supporting framework of the tumor, including extracellular 
matrix proteins, growth factors, cellular interactions with 
fibroblasts, macrophages, endothelial cells, bone cells 
(osteoblasts and osteoclasts) and adipocytes. In turn, 
MM dysregulates the BM, resulting in osteolytic lesions, 
anemia, renal failure, and immunosuppression. The 
overall survival of treated patients below 68 is 8-9 years; 
the event free survival is 3-4 years [76]. First-line therapy 
includes high dose corticosteroids (dexamethasone) and 
other cytolytic agents such as bortezomib, thalidomide 
and lenalidomide (LEN) or melphalan [77-81]. 
Depending on the status of the patient this can then 
be followed by autologous stem cell transplantation 
(ASCT). Consolidation and maintenance therapy after 
ASCT are attractive strategies to increase the beneficial 
effects. However, even after this intensive treatment, in 
the majority of patients some MM cells remain. This is 
called “minimal residual disease” (MRD) [81]. Eventually, 
these cells can grow out, induce relapse and patients 
ultimately become refractory to all treatment options. 
Despite the different chemotherapeutic modalities and the 
many clinical trials to eradicate this disease, MM is still 
incurable. 
Different research groups provided evidence of 
type I NKT cells being quantitatively and qualitatively 
defective in MM, subsequently hampering their anti-
tumor effects [82] (Figure 2). The group of Dhodapkar et 
al. demonstrated that type I NKT cells are still detectable 
in the blood and tumor bed of MM patients at both early 
and progressive stages of the disease but they could 
observe that advanced stages of MM were associated with 
the progressive loss of the ability of iNKT cells to secrete 
IFN-γ. The type I NKT dysfunction could be overcome in 
vitro by using dendritic cells (DCs) pulsed with α-GalCer. 
When MM patients were injected with αGalCer loaded 
DCs (at monthly interval 2 injections), their type I NKT 
cell pool expanded 100 fold, with improved function 
and these effects lasted for several months. Altogether, 
these results suggest that clinical progression is linked 
to an acquired but potentially reversible defect in type I 
NKT cells and supports the hypothesis that iNKT cells 
help in controlling the malignant growth of the MM 
cells [82, 83]. Together with other groups they further 
demonstrated that MM cells are expressing CD1d and are 
sensitive to lysis induced by type I NKT cells, making 
them interesting targets for NKT directed therapies [82]. 
Spanoudakis et al has shown that CD1d was highly 
expressed on premalignant and early myeloma. With 
disease progression CD1d expression levels were down-
regulated and eventually lost altogether in advanced MM 
patients and in most of the studied myeloma cell lines, 
leading to a reduction in survival [84]. Engagement of 
CD1d by anti-CD1d monoclonal antibodies was able 
to induce myeloma cell death in vitro which was not 
induced by caspase-activation but was rather associated 
with overexpression of the pro-apoptotic protein Bax and 
mitochondrial membrane potential loss [84]. 
We recently investigated the number, activity 
and characteristics of type I NKT cells in the syngeneic 
preclinical 5T33MM murine model, an immunocompetent 
model which mimics the human disease closely [85]. 
Consistent with previous observations, our results 
demonstrated a dramatic drop of type I NKT cell numbers 
in the liver and spleen at the end stage of the disease. 
This decline was also detectable in the 5T2MM model, 
a slower progressing model. The ability of murine type 
I NKT cells to secrete IFN-γ in response to α-GalCer 
loaded mature DCs was abrogated at the end stage of the 
disease due to a decline in NKT number. Treatment with 
α-GalCer loaded DCs significantly increased the survival 
of MM diseased mice for 1 week when they were injected 
on the same day of 5T33MM inoculation [85]. The group 
of Mattarollo et al. could also demonstrate that a single 
vaccination of irradiated tumor cells pulsed with α-GalCer 
was able to inhibit MM development and prolong survival 
of Vk*MYC mice [86]. Nonetheless, the expression of 
CD1d in the 5T33MM model was still high at the end 
stage of MM and lacked the potency to activate type I 
NKT cells and cause tumor cell lysis after stimulation with 
α-GalCer. We also found that the 5T33MM cells lacked 
the necessary co-stimulatory molecules such as CD40, 
CD80 and CD86 potentially explaining our observations 
[85]. Hong et al. however demonstrated that a vaccine 
consisting of αGalCer-loaded MOPC315BM myeloma 
cells efficiently promoted anti-tumor immunity, slowed 
down tumor growth, induced established tumor regression 
and protected (surviving) mice from tumor rechallenge. 
Strong humoral immune responses, including myeloma-
specific antibodies and cellular immune responses, such 
as myeloma-specific CD8+cytotoxic and memory T cells 
were induced and Treg cells were significantly decreased 
[87]. It is known that MM correlates with a high vascular 
index. Targeting angiogenesis is therefore an important 
therapeutic tool to reduce MM progression. We were able 
to demonstrate that the conditioned medium of α-GalCer 
stimulated NKT cells induced a reduction in endothelial 
cell proliferation, migration and network formation and 
increased their apoptosis in vitro, whereby the JAK-STAT 
signalling pathway was highly activated. Furthermore, 
injecting α-GalCer in vivo led to a significant reduction in 
microvessel density [88].
Song et al. succeeded in activating and expanding 
CD1d-restricted type I NKT cell lines isolated from newly 
diagnosed and advanced MM patients [89]. The results 
showed that type I NKT cells could secrete Th1-polarized 
cytokines in response to α-GalCer loaded DCs or primary 
MM cells and that they could induce direct cytotoxicity 
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against the primary MM cells. LEN, a derivate of 
thalidomide and one of the novel drugs used to treat MM, 
is effective in inducing complete or good partial responses 
and is able to improve the survival of MM patients [74]. It 
has among others immunomodulatory properties, although 
the specific cellular targets and molecular mechanisms 
responsible for the immunomodulatory actions of LEN 
have not been fully elucidated yet. Song et al. provided 
preclinical evidence that a combination of type I NKT 
immunotherapy with LEN led to an increased Th1 cytokine 
production and reduced Th2 cytokine levels [89] (Figure 
2). The group of Chang et al. observed an even greater 
effect when LEN was combined with dexamethasone 
[83]. They further obtained striking results when α-GalCer 
loaded DCs were injected in 3 MM patients at stage III. 
Intravenous injection of α-GalCer loaded mature DCs 
in these patients, who had received chemotherapy and 
stem cell transplantation, gave a remarkable boost in 
the expansion of circulating type I NKT cells which 
sequentially resulted in a reduction of the serum and urine 
levels of M-protein. A sustained expansion of type I NKT 
cells, lasting 3 months after vaccination, was observed in 
one of the patients. An increase of different factors such as 
IL-12 p40, IP-10 and MIP-1β in the patient serum levels 
were detected [83]. Confirming previous in vitro results, 
Dhodapkar et al found that LEN had the ability to enhance 
type I NKT expansion in presence of α-GalCer and to 
stimulate IFN-γ secretion by NKT cells in both healthy 
donors and MM patients (Figure 2). The combination 
therapy provided downstream activation of NK cells, 
monocytes and eosinophils by upregulating surface 
receptors such as NKG2D, CD56 and CD16, ultimately 
promoting tumor suppression [90]. 
Data on type II NKT cells and MM are scarcely 
present in literature. However, their increase in the 
peripheral blood of MM patients was reported by Chang 
DH et al. Those type II NKT cells appeared to be specific 
for lyso-PC and had a Th2-skewed profile with high 
expression levels of IL-13 [40]. Taken together, these data 
suggest that NKT cells are a particularly attractive subset 
to target and encourage the rationale for type I NKT cell-
mediated immunotherapy in MM. 
NAturAl killer t cells: 
ChAllenGes
The use of α-GalCer and other glycolipids to 
activate type I NKT cells has engendered a lot of 
preclinical success in mice, leading to multiple clinical 
trials in humans (Table 1). However, the benefits for 
patients remains limited since the translation of these 
preclinical benefits into clinical trials is associated with 
some challenges [91]. As noted above, the frequency of 
type I NKT cells is much lower in humans than in mice 
and numbers are more variable between individuals 
which possibly can contribute to the heterogeneity in 
clinical responses [16, 92, 93]. In advanced stages of 
cancers, like MM, the number and function of type I 
NKT cells is often reduced. Therefore, the effects of NKT 
activation may be less amplified in humans than in mice 
[91]. Moreover, we can also presume that patients that 
participated in these trials had a much more advanced 
disease than mice in which α-GalCer had a significant 
greater therapeutic effect. It is worth to mention that it 
has been demonstrated in mice that following injection of 
α-GalCer, type I NKT cells cannot be restimulated for at 
least two months [94-96]. This means they are sensitive to 
anergy which is a property that can also explain the lack 
of success in humans. Being confronted in our research 
with this problem as well we have the opinion that this 
is one of the major obstacles which need to be overcome 
to give a future to an NKT-based immunotherapeutic 
approach. Specifically, marked increase in programmed 
death-1 (PD-1) expression after α-GalCer stimulation has 
been shown to hamper the beneficial and/ or long lasting 
effects of NKT cell-mediated treatment [97]. We also 
believe that a suboptimal activation due to uncontrolled 
distribution of α-GalCer remains a big problem. Therefore, 
it would be of great value to develop new α-GalCer carrier 
systems (e.g. nanovectors, liposomes and exosomes) to 
optimize NKT-cell responses and cancer immunotherapy 
[100, 101]. Also the different (sub)populations, their 
adaptable reactivity against ligand agonists and the 
different APCs involved in the antigen presentation add 
more complexity and can explain the paradox regarding 
the NKT cell subpopulations. Furthermore, it is possible 
that the presence of different endogenous self-antigens, 
leading to auto-reactivity, can activate different pathways 
in the NKTs that are modulating the NKT cell - cell 
talk [102]. Finally, our knowledge of the presence of 
endogenous ligands is still very limited hampering our true 
understanding of NKT cell biology [27].
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